These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10575268)

  • 1. Sensitivity of BCG to modern antibiotics.
    Durek C; Rüsch-Gerdes S; Jocham D; Böhle A
    Eur Urol; 2000; 37 Suppl 1():21-5. PubMed ID: 10575268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference of modern antibacterials with bacillus Calmette-Guerin viability.
    Durek C; Rüsch-Gerdes S; Jocham D; Böhle A
    J Urol; 1999 Dec; 162(6):1959-62. PubMed ID: 10569547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.
    van der Meijden PM; van Klingeren B; Steerenberg PA; de Boer LC; de Jong WH; Debruyne FM
    J Urol; 1991 Aug; 146(2):444-6. PubMed ID: 1856950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
    Böhle A; Rüsch-Gerdes S; Ulmer AJ; Braasch H; Jocham D
    J Urol; 1996 Jun; 155(6):1892-6. PubMed ID: 8618281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains.
    Chen JM; Uplekar S; Gordon SV; Cole ST
    PLoS One; 2012; 7(8):e43467. PubMed ID: 22912881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fate of bacillus Calmette-Guerin after intravesical instillation.
    Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
    J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
    Akselband Y; Cabral C; Shapiro DS; McGrath P
    J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
    Watts MR; Taylor PC; Sintchenko V; Whelan CM; Farnsworth RH; Jones P; Jelfs P; Carr D; Goldberg H
    Clin Infect Dis; 2011 Jan; 52(1):86-8. PubMed ID: 21148524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.
    Pommier JD; Ben Lasfar N; Van Grunderbeeck N; Burdet C; Laouénan C; Rioux C; Pierre-Audigier C; Meybeck A; Choudat L; Benchikh A; Nguyen S; Bouvet E; Yeni P; Yazdanpanah Y; Joly V
    Infect Dis (Lond); 2015; 47(10):725-31. PubMed ID: 26077036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin].
    Shimasaki N; Yamasaki I; Kamada M; Syuin T
    Hinyokika Kiyo; 2001 Apr; 47(4):281-4. PubMed ID: 11411106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections.
    Malhotra P; Farber BF
    Can J Urol; 2011 Jun; 18(3):5671-5. PubMed ID: 21703038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
    Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM;
    Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains.
    Secanella-Fandos S; Luquin M; Julián E
    J Urol; 2013 Feb; 189(2):711-8. PubMed ID: 22982433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
    Durek C; Jurczok A; Werner H; Jocham D; Bohle A
    J Urol; 2002 Aug; 168(2):826-31. PubMed ID: 12131375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.
    Proctor DD; Chopra S; Rubenstein SC; Jokela JA; Uhl L
    Am J Gastroenterol; 1993 Jul; 88(7):1112-5. PubMed ID: 8317415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
    Hofbauer SL; Shariat SF; Chade DC; Sarkis AS; Ribeiro-Filho LA; Nahas WC; Klatte T
    Urol Int; 2016; 96(1):46-50. PubMed ID: 26555711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
    Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
    J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guérin.
    Harding GE; Lawlor DK
    J Vasc Surg; 2007 Jul; 46(1):131-4. PubMed ID: 17606130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.